Artiva Biotherapeutics (NASDAQ:ARTV) Given “Outperform” Rating at Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock. Wedbush’s price target points to a potential upside of 394.51% from the stock’s current price.

Several other research analysts have also commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Trading Down 8.8 %

ARTV stock opened at $3.64 on Tuesday. The company has a fifty day simple moving average of $4.84 and a two-hundred day simple moving average of $9.33. Artiva Biotherapeutics has a 52 week low of $3.37 and a 52 week high of $17.31.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. RA Capital Management L.P. purchased a new stake in Artiva Biotherapeutics in the 3rd quarter valued at about $152,234,000. Franklin Resources Inc. purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $7,435,000. Geode Capital Management LLC grew its holdings in Artiva Biotherapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $4,506,000. Finally, Wellington Management Group LLP acquired a new stake in Artiva Biotherapeutics in the third quarter worth about $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.